Afibrinogenemia is a rare disorder characterized by the absence of detectable fibrinogen
due to genetic mutations.[1] The common presentation is spontaneous or unusual bleeding with minor trauma. But
the recent case report and review by Santoro et al highlights that many patients present
with thrombosis with or without bleeding, representing challenging clinical situations.[2] Here, we add insight into management of these patients with a case of a patient
with afibrinogenemia who developed recurrent arterial stenosis refractory to dual
antiplatelet therapy and fibrinogen replacement treated with the novel protease-activated
receptor 1 (PAR-1) antagonist vorapaxar.
Fibrinogen is a glycoprotein that is produced in the liver and stored in platelet
α granules after uptake from plasma.[1] Fibrinogen functions in fibrin clot formation, thrombin regulation, platelet aggregation,
and fibrinolysis. Afibrinogenemia is an autosomal recessive disorder associated with
a quantitative deficiency of fibrinogen and a prevalence of 1 in 1,000,000.[3] The clinical manifestations of afibrinogenemia include umbilical cord hemorrhage
and bleeding in the gastrointestinal (GI) tract, genitourinary tract, mucosa, skin,
and the central nervous system.[4] Approximately 30% of patients with afibrinogenemia may also have thrombotic complications
due to the antithrombin function of fibrinogen. Rarely patients may have both bleeding
and thrombotic complications related to the disease.[5]
[6] Treatment for hemorrhage includes antifibrinolytics and/or fibrinogen replacement
therapy with fresh frozen plasma, cryoprecipitate, and plasma-derived fibrinogen concentrate.[7] In the setting of a thrombotic phenotype, there is no clear consensus, but treatment
with low molecular weight heparin, antiplatelet agents, vasodilators, lepirudin, and
direct thrombin inhibitors with fibrinogen replacement therapy has been used.[8] We present a case of a patient with bleeding and thrombotic complications associated
with congenital afibrinogenemia treated with the novel PAR-1 antagonist vorapaxar
(Zontivity, Aralez Pharmaceuticals Inc.) and fibrinogen replacement therapy ([Fig. 1]).
Fig. 1 Multiple agents inhibit platelet activation but only vorapaxar inhibits protease-activated
receptor 1 (PAR-1). Platelet activation pathways and drug molecular targets. Thrombin
binds to PAR-1, which leads to shape change, phospholipase C (PLC) activation, thromboxane
A2 (T × A2) generation, and activation of the glycoprotein (GP) IIb/IIIa receptor,
resulting in sustained platelet aggregation. Cyclooxygenase 1 (COX-l) catalyzes the
production of T × A2, a potent platelet aggregator, generated by platelets activated
by thrombin and other agonists. Adenosine 5′-diphosphate (ADP) binds to its 7-transmembrane
domain receptors, P2Y1 and P2Y12, to activate platelets. P2Y1 is coupled to Gαq and
G12. Gαq is linked to a signaling pathway involving PLC activation, resulting in a
rise in the intracellular calcium concentration ([Ca + 2] i) and protein kinase C
(PKC) activation, leading to GP IIb/IIIa activation and transient platelet aggregation.
G12 mediates platelet shape change. P2Y12 is linked to Gai-coupled signaling cascades
associated with adenyl cyclase (Ac) downregulation and decreased cyclic-3′,5′-monophosphate
(cAMP) production, which mediates GP IIb/IIIa receptor activation, leading to sustained
platelet aggregation. (Reproduced with permission of Di Minno MND, Guida A, Camera
M, Colli S, Di Minno G, Tremoli E. Overcoming limitations of current antiplatelet
drugs: a concerted effort for more profitable strategies of intervention. Ann Med 2011;43(7):531–544, under open access license https://creativecommons.org/licenses/by/2.0/legalcode with no alterations.)
The patient is a 34-year-old Hispanic woman with a past medical history of sensorineural
hearing loss, type 1 renal tubular acidosis, GI bleed, and congenital afibrinogenemia.
The patient's history of afibrinogenemia was associated with episodes of gingival
bleeding, hemarthrosis, menorrhagia, and hematemesis. She was treated with on-demand
infusions of cryoprecipitate for many years with control of symptoms. In April 2010,
she began having recurrent painful edema in her right great toe that progressed to
her other digits and foot and was relieved with cryoprecipitate infusions. Over the
next year, the pain became more persistent. Evaluation for ischemia with an angiogram
demonstrated stenosis of the infrarenal aorta and narrowing of the dorsalis pedis
artery. In June 2011, she was started on fibrinogen concentrate infusion to reduce
the risk of bleeding intraoperatively and underwent endovascular aortic repair with
endoprosthetic stents placed to dilate the distal aortic stenosis. She was treated
with clopidogrel 75 mg orally (PO) once daily (QD), aspirin 81 mg PO QD, and prophylactic
fibrinogen concentrate infusions 2000 mg IV (intravenous) once weekly due to the history
of GI bleeding. She developed recurrent microembolic phenomena after cessation of
clopidogrel, which was restarted. In July 2016, she presented with complaints of cramping
lower extremity pain on exertion that had progressed to pain at rest and was admitted
for critical limb ischemia. Angiogram of the infrarenal abdominal aorta revealed multifocal
hypodense plaques in the proximal third of the stents bilaterally consistent with
mild-to-moderate in-stent stenosis ([Figs. 2] and [3]). She then underwent bilateral common femoral artery exploration with kissing balloon
angioplasty with resolution of the stenosis and patent bilateral lower extremities
postprocedure. After discharge from the hospital, there was grave concern that she
had developed in-stent stenosis while on clopidogrel and aspirin. Clopidogrel was
discontinued and she was started on vorapaxar 2.08 mg PO QD, and the same dose of
aspirin was continued. Surveillance angiogram 6 and 12 months after starting vorapaxar
revealed patent infrarenal stents bilaterally and improved multifocal plaques in the
left and right common iliac arteries. The plan was to discontinue vorapaxar after
12 months of therapy, but given patient's response and tolerability to the therapy,
it has been continued to date.
Fig. 2 Intra-abdominal stents with left common iliac stenosis (White arrow).
Fig. 3 Bilateral intra-abdominal stent stenosis (White arrows).
Treatment recommendation per the 2016 Delphi consensus in patients with bleeding phenotype
of afibrinogenemia is to start secondary prophylaxis after first life-threatening
bleeding episode.[8] Fibrinogen replacement therapy is a risk factor for thromboembolism, although the
exact incidence of events associated with the treatment is unknown. In patients with
thrombosis, fibrinogen replacement therapy should be administered concurrently with
low molecular weight heparin. For patients on antiplatelet therapy, fibrinogen replacement
should be considered based on the risk of bleeding. Our patient had a history of GI
bleeding and therefore she was continued on replacement therapy for the duration of
antiplatelet therapy. The proposed mechanism for the development of thrombosis in
patients with congenital afibrinogenemia is lack of antithrombin I activity of fibrin.
Normally, this activity of fibrin includes sequestering free thrombin, which downregulates
thrombin activity and decreasing subsequent platelet activation.[9] But in patients with afibrinogenemia, free thrombin is not sequestered, and increasing
levels of free thrombin lead to platelet activation through the PAR-1 and a prothrombotic
state.[10] In addition, increasing thrombin promotes proliferation of vascular smooth muscle
cells, which may have contributed to stenosis in this patient. PAR-1 is found on the
surface of platelets and vascular endothelium. Thrombin levels were not measured in
this patient, but her episodes of limb pain improved with fibrinogen replacement therapy,
which highlights the possibility of elevated thrombin activity as the cause and reduction
of its activity when fibrinogen was replaced.
Vorapaxar is a competitive and selective antagonist of PAR-1 thrombin receptor on
platelets. In a randomized, double-blind, placebo-controlled trial (TRA2°P-TIMI 50)
of vorapaxar, patients with a history of myocardial infarction, ischemic stroke, or
peripheral arterial disease (PAD) were randomized to vorapaxar or placebo.[11] Vorapaxar reduces acute limb ischemia in patients with symptomatic PAD. Our patient
was started on vorapaxar as an antiplatelet therapy for increased thrombin activity,
which was thought to be causing thrombosis and stenosis. If the development of thrombosis
in patients with congenital afibrinogenemia is secondary to excess thrombin, then
blockade of PAR-1 with this new antiplatelet agent would be a rational therapy. As
there is an increased risk of bleeding with the antiplatelet agents, fibrinogen replacement
would need to be determined on a case-by-case basis. While vorapaxar activity on platelet
aggregation has been evaluated, the effect on endothelial cells and smooth muscle
cells has not been studied and is an area for further research.
In conclusion, vorapaxar targets the thrombin pathway and is a reasonable treatment
option for refractory thrombosis in patients with afibrinogenemia. Further research
will need to focus on management strategies of these complex patients.
